Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Chronic hepatitis caused by hepatitis C virus infection is one of the leading causes of liver cirrhosis and hepatocellular carcinoma globally. Over the last few years, there have been significant advances in our understanding of the immunopathogenesis of this infection, as well as revolutionary developments in the therapeutic armamentarium. The introduction of a number of new oral antiviral agents is already delivering major benefits to patients as they are generally well tolerated and are associated with excellent response rates in the majority. Nonetheless, a number of clinical scenarios remain challenging and research is ongoing in these areas. In this update, we review developments in both basic as well as translational research in the field.

Original publication

DOI

10.7861/clinmedicine.15-6-s33

Type

Journal article

Journal

Clin Med (Lond)

Publication Date

12/2015

Volume

15 Suppl 6

Pages

s33 - s36

Keywords

HCV, HLA, T cells, direct-acting antivirals, vaccines, Antiviral Agents, Hepacivirus, Hepatitis C, Chronic, Humans, Viral Hepatitis Vaccines